Global Pharmaceutical Services Inc. (GPSI), a provider of research and development support to the worldwide pharmaceutical and biotechnology industry, has outsourced some clinical development to India.

GPSI has entered into an exclusive partnership with Abridge Clinical Research Pvt. Ltd, a research and development company located in Mumbai, India. "We are delighted in working with such an experienced company like Abridge Clinical as their expertise and core values are very similar to those at GPSI," according to Dr. Garland A. Johnson, Senior Vice President, GPSI.

"India has become the hub of clinical research, as sponsors and Contract Research Organisations (CROs) from the USA can benefit from this relationship due to fast recruitment, good quality and cost effectiveness. In today's scenario of recession, India has become the favourite place for outsourcing the clinical studies. We are delighted to be working with GPSI in the offering of these services," as stated by Dr. Emran Khan, Director of Abridge.

The new deal will see Abridge offer Contract Research Organisation (CRO) selection for specific clinical programs, monitoring of clinical studies, auditing, quality assurance, design and conduct of clinical studies, faster patient enrolment, in-country sponsor representative, medical writing, data management, bio statistical services, and regulatory support.